Tourette syndrome and tic disorders

• A tic is a sudden, rapid, recurrent, non-rhythmic movement or vocalisation, usually in bouts, that waxes and wanes in timing and kind.
• Tourette syndrome is a neurodevelopmental disorder: both motor and phonic (vocal) tics beginning before age 18 and persisting for more than 12 months, without another cause such as a drug, infection or movement disorder.
• It is common rather than rare in childhood: about 0.3–1% of school-aged children are affected, and males more often than females.^[4][6]
• Isolated Tourette syndrome is the exception: up to 88% of people have at least one additional psychiatric disorder during life, most often ADHD (30–55% in clinical series) and OCD (10–50%).^[4][6]
• Peak tic severity is usually around ages 10–12 years, and most people still have only mild or no tics after adolescence; up to 23% of affected individuals have persistent, sometimes severe, tics into adulthood.^{[6] [4]}
• CBIT — combined habit reversal, relaxation and a functional intervention — is the therapy with the strongest evidence and is recommended before medicines. Medicines such as alpha-2 agonists and antipsychotics are added for severe or disabling tics, and complete disappearance of tics is uncommon.^{[4][5] [3]}

By the end of this page you should be able to:

1. Define a tic and distinguish motor (simple and complex) from phonic tics, and both from stereotypies and functional tic-like movements.
2. State the DSM-5 diagnostic criteria for Tourette syndrome and the main ICD-11 categories, and explain how Tourette syndrome differs from provisional and persistent tic disorders.
3. Describe the typical age of onset, sex pattern, prevalence and natural history.
4. Identify the motor features of a tic, the premonitory urge, suppressibility and the effect of attention and stress.
5. Explain the cortico-basal ganglia mechanism proposed for tics, including premonitory-urge processing and the dopamine and inhibition hypotheses.
6. Assess a person with tics for comorbid ADHD, OCD, anxiety, depression and self-injurious behaviour.
7. Create an investigation and severity-measurement plan, including when no tests are needed.
8. Manage tics stepwise with psychoeducation, CBIT, alpha-2 agonists, antipsychotics and other agents, including monitoring, tapering and referral. ^[4]

A tic is a sudden, rapid, recurrent, non-rhythmic movement or vocalisation, usually occurring in bouts, that alters in number, frequency, intensity, complexity and kind as days and years pass.^[2] Motor tics involve the voluntary musculature and can be simple (one muscle group — an eye blink, a nose twitch) or complex (a head turn with a shoulder shrug, touching, tapping). Phonic (vocal) tics are any sound produced by airflow through the nose, mouth or throat, from throat clearing and grunting to words and phrases.^[2] Tics are suggestible, often preceded by a premonitory urge, feel partly voluntary when performed, and can be suppressed briefly at the cost of inner tension.^[2]

The word "involuntary" is often applied, but the experience is better described as semi-voluntary: most people feel a build-up of sensory tension that is relieved only by the tic.^[2]

Tourette syndrome and the chronic (persistent) tic disorders were historically viewed as separate but are now considered a single spectrum from mild, transient tics to severe, disabling Tourette syndrome.^[2] The diagnosis of Tourette syndrome is clinical: there must be at least two motor tics and at least one phonic tic, beginning before age 18, present for more than 12 months, not due to a drug, infection, head injury, other neurological condition or another cause.^[5] A single motor or single phonic tic lasting more than a year is classified as persistent (chronic) motor or vocal tic disorder. Tics present for less than a year are a provisional (transient) tic disorder. ^{[1][2][5] [4]}

Simple tics are confined to one muscle group or brief sound. Complex tics involve coordinated movements of several muscle groups or words and phrases, and can look like goal-directed behaviour. Coprophenomena — obscene words or gestures — are reported in about 15–20% in European series and in approximately 28% of individuals in a recent review.^[2][5][6] Stereotypies are repetitive, often rhythmic and continuous movements of a fixed pattern that usually begin between ages 0 and 3 years; they are not associated with a premonitory urge and are common in autism spectrum conditions.^{[2] [1]}

Clinical assessment uses DSM-5 in many settings, whereas ICD-11 groups tic disorders under movement disorders. The European Society for the Study of Tourette Syndrome (ESSTS) agrees with ICD-11 relocation for surveillance, but emphasises the neurodevelopmental nature of tics and therefore the practical value of the DSM-5 neurodevelopmental framing.^[1][3]

Tourette syndrome and chronic tic disorders are among the most common movement disorders diagnosed in childhood. Prevalence figures vary widely with age and with how strictly the disorder is sought: European and American series report Tourette syndrome in about 0.3–1% of children and adolescents and in only 0.002–0.08% of adults with a formal diagnosis.^[1][6] ESSTS places Tourette syndrome at 0.3–1% of the general population and notes that tics occur in young people before age 18 in most cases.^[1] Tourette syndrome was once thought to be rare because mild cases were missed, and older literature reported serious illness in only 0.03%. Modern school-based and population studies give the higher figures quoted above.^{[4][6] [5]}

Sex is strongly skewed: males are affected about 3 to 4 times as often as females in childhood series, with male-to-female ratios reported from 3:1 up to 4.3:1. The skew is less pronounced in adults with the condition, partly because affected males are more likely to present with severe tics.^[1][6] Onset is usually between ages 3 and 8, the mean age at first tic is around 5 years, and up to 40% of patients report first tics at an even younger age.^[1][6] The condition is found worldwide, across all races, although presentation and diagnosis depend on local awareness. All guidelines quoted here come from high-income regions, so worldwide practice is extrapolated rather than quantified. ^[3]

Tourette syndrome is highly heritable: large population-based and genome-wide association studies estimate that genetic variants account for roughly 77–92% of heritability, with similar genetic risk in males and females.^[6] Monogenic forms are rare (fewer than 2%), reported in genes involved in neuronal and dendrite development, axonal guidance and membrane stability (such as SLITRK1–6, CELSR3, CNTN6, NRXN1), histamine synthesis (histidine decarboxylase) and opioid signalling.^[6] More commonly Tourette syndrome is polygenic, with multiple small-effect variants, and the same genetic background underlies both Tourette syndrome and persistent tic disorder.^[6]

Family and twin studies give heritability estimates of roughly 28–56%. Parents of affected children often have tics, obsessive-compulsive symptoms or ADHD themselves.^[2] Maternal psychiatric history has also been associated with Tourette syndrome in offspring, consistent with the known genetic correlation among psychiatric disorders.^[6]

Stress, anxiety, fatigue, excitement, sensory stimuli and infection can worsen tics or trigger new ones. The triggers most commonly reported by patients are stress, fatigue, excitement, concentration on the premonitory urge and sensory overload.^[1][2] Suppression, focused activity and social situations often temporarily reduce tic frequency, which explains why a person may be virtually tic-free in the clinic but symptomatic at home.^[1][6] Prenatal and perinatal factors (low birth weight, prenatal distress, maternal smoking or alcohol during pregnancy) and childhood psychosocial stress have been associated with more severe tics, but no single environmental factor is necessary or sufficient and none is directly modifiable in routine care.^[6] Whether group A streptococcus causes tics was tested in the multinational EMTICS study, which found no specific relationship; antibiotics, immune globulin or plasmapheresis for assumed post-streptococcal tics have not shown efficacy, and PANDAS-related scales add nothing to diagnosis.^[2]

Useful clinical risk markers are male sex, childhood onset, a first-degree relative with tics or OCD, comorbid ADHD or obsessive-compulsive symptoms, tics starting as simple motor tics at ages 3–8, and a family environment that increases psychosocial stress.^[1][2][6] Adults with Tourette syndrome have an increased risk of suicide attempt and death by suicide compared with controls, even after adjusting for comorbid psychiatric illness, so suicidality should be asked about at diagnosis and at follow-up.^[4]

Tourette syndrome is understood as a neurodevelopmental disorder of cortico-basal ganglia networks rather than a movement disorder of a single structure. Imaging and neuropathology point to dysfunction of the sensorimotor cortico-basal ganglia network, with changes in the inhibitory microcircuitry of the striatum.^[6] Autopsy series have found fewer inhibitory GABA-containing parvalbumin-positive interneurons and cholinergic interneurons in the striatum of people with Tourette syndrome compared with controls.^[6] These inhibitory neurons normally pace movements initiated in cortex; with less inhibition, small fragments of action escape inappropriately as tics. Volitional inhibition measured by proactive or reactive tests is largely preserved, whereas automatic suppression of unwanted action is impaired, and the degree of automatic-inhibition impairment correlates with tic severity.^[6]

Three hypotheses currently coexist: (1) tics arise from reduced inhibition in the sensorimotor cortico-basal ganglia loop; (2) tics are exaggerated, persistent motor habits reinforced by phasic dopamine and reward-guided learning, with tonic and phasic dopamine out of balance in direct and indirect pathways; (3) the premonitory urge is generated by abnormal interoceptive processing in the insula plus exteroceptive processing in sensorimotor cortex, and action release through the anterior cingulate then executes the tic.^[6] Observational work suggests that premonitory urges have a consistent temporal link with motor tics in only 57–66% of adults, depending on how urges are measured, so absence of urge does not exclude Tourette syndrome.^[6]

Neurological examination is otherwise normal in uncomplicated Tourette syndrome, and EEG, brain imaging or routine laboratory tests are not needed. Low-frequency (1–10 Hz) power recorded in the centromedian thalamus and anterior pallidum during deep brain stimulation for refractory cases is a research marker of premonitory urges and tics, not a routine diagnostic test.^[6]

From this model several clinical observations follow: tics worsen with stress and ease with focused attention because attention changes cortical drive; premonitory urges explain why habit reversal works; and dopaminergic, noradrenergic and serotonergic medicines have a rational place, although each is empirically only modestly helpful on average.^[4][6]

Ask the person or parent to describe matters in their own words. Tics usually begin as simple motor tics of the face, head or neck — blinking, facial grimacing, head jerks. Phonic tics (sniffing, throat clearing, grunting) often appear 1–2 years later, so an isolated simple motor tic at age 4 can be the first chapter of a tic disorder.^[1][6] New tics are added and old ones disappear, giving the characteristic waxing-and-waning repertoire.^[1][6]

Most people can suppress a tic for minutes to an hour, at the cost of mounting tension and rebound. Tics worsen with stress, fatigue and excitement and improve with focused mental or physical activity; they usually disappear during sleep.^[1][6] Some people report no premonitory urge, particularly young children and those with simple motor tics; awareness increases with age.^[1][2]

Complex tics may involve obscene or socially inappropriate gestures or words (coprophenomena). Despite being the best-known feature, they occur in 10–28% of affected people and are usually mild and controllable; functional tic-like movements (see below) are more likely than Tourette syndrome to include compound obscene phrases.^[2][5][6]

Self-injurious tics are reported in about 17% of individuals in a large series, and at least a third of all patients with TS in clinical practice, often in the setting of comorbid obsessive-compulsive disorder; they can produce tissue damage requiring hospitalisation.^[5][6] Inquiries about self-injury, anger outbursts and rage are not optional: rage attacks occur in roughly 25–75% of people, and suicidality is higher than in the general population.^{[2][4] [1]}

Observation is the examination. Watch the person in a comfortable setting and ask permission to film. Look specifically for:

• Rapid, brief, jerky (clonic) movements, sustained dystonic or tonic postures lasting more than 300 ms, or a mixture;
• Simple motor tics restricted to one muscle group;
• Complex motor sequences, touching, tapping or "just-right" repetitive adjustment;
• Simple noises or full words and phrases;
• Suppressibility: can the person reduce the tic rate when asked? (Suppressibility alone does not separate tics from functional movements.)
• Premonitory urge: ask "do you feel something before it happens?" — but expect a negative answer from young children.
• Stimulus-bound tics triggered by touch, sound or a thought;
• Blocking of ongoing movement or speech without loss of consciousness.

The neurological examination should be normal in an uncomplicated tic disorder. Unusual findings such as asymmetry, progressive course, focal seizure semiology, atypical postures or late onset should redirect the work-up toward other hyperkinetic movements, dystonia, myoclonus or epilepsy.^[2]

Screen specifically for ADHD, OCD, anxiety, depression, oppositional defiant disorder, autism spectrum characteristics, self-injury and suicidal thoughts, because comorbidity, rather than tic severity, drives quality of life. In population-based and clinic-based studies, up to 88% of people with Tourette syndrome have at least one additional psychiatric disorder in their lifetime, and an estimated 58% have two or more; only a minority have "pure" Tourette syndrome.^[4][6] Up to 22.8% of children with Tourette syndrome meet cut-off criteria for autism spectrum disorder, mainly on the restricted and repetitive behaviours subscales, which can overlap with obsessive-compulsive symptoms.^{[2] [1]}

Misdiagnosis is common: one estimate is that diagnosis is delayed by 3–11 years after onset and that about 73% of people receive an initial incorrect diagnosis, based on patient self-report.^[6] The main alternatives are set out below.

The diagnosis is clinical. For most people, no test is needed beyond a careful history and observation. ESSTS recommends a neurological and, when clinically indicated, psychiatric examination, but neuroimaging, EEG and blood tests add nothing to the diagnosis of a primary tic disorder and should be used only when red flags appear or to rule out a secondary cause.^[1][2] Red flags that justify investigation include late or adult onset, abrupt severe presentation, focal or progressive abnormal neurological findings, asymmetric postures, suspected epilepsy, cognitive decline, recent streptococcal illness offered as an explanatory model, or tics with suspected drug or toxin exposure.

Severity is measured, not diagnosed. The Yale Global Tic Severity Scale (YGTSS) remains the standard research and clinical tool: total tic score 0–50, with a separate global impairment score of 0–50 and a combined total of 0–100.^[5] Other commonly used tools are the Tourette Syndrome Clinical Global Impression, the Shapiro Tourette Syndrome Severity Scale and the Premonitory Urges for Tics Scale.^[2] ESSTS recommends combining rating scales, direct observation inside and outside clinic, and video assessment, because tics are variable and often hidden in the examination room.^[2][6]

Diagnostic criteria below are paraphrased from DSM-5 and ICD-11, never quoted verbatim, and should be confirmed against the current editions.

Comorbid conditions, not tics, are usually what brings a person to clinic and what needs treating. Psychiatric comorbidity is the rule: clinic-based studies report 55–60% of people with Tourette syndrome have ADHD, 22–66% have obsessive-compulsive symptoms or disorder, 10–50% meet diagnostic criteria for OCD, 30–50% of referred children with Tourette syndrome have ADHD, and up to 88% have at least one additional psychiatric disorder during life.^[1][2][4][6] ESSTS Part III gives 30–50% ADHD prevalence in referred children and "up to 50%" for OCD. Studies that measure clinically referred populations give the higher ranges; milder cases in the community probably have lower rates.^[1][2][4] Because sources differ, the individual person needs assessment, not a headline figure.

ADHD often begins earliest (median age 5 years) and is strongly linked to functional impairment in children with Tourette syndrome.^[4][6] Alpha-2 agonists (clonidine, guanfacine) improve both tics and ADHD and are a good first medication when both are present. Psychostimulants do not worsen tics overall in clinical trials, although a transient increase can occur; if it persists, atomoxetine is a reasonable alternative.^[2][4][5] ADHD symptoms may improve in adolescence, but some people need treatment into adulthood.^[4]

OCD often begins at a median of 7 years and the symmetry/"just-right"/evening-up symptoms are particularly common in Tourette syndrome.^[2][6] ESSTS guidance and the AAN guideline agree that cognitive behaviour therapy for OCD is first-line when tics are present, because trials in children suggest those with tics do not respond as well to selective serotonin reuptake inhibitors as those without tics, yet respond as well to cognitive behavioural treatment.^[2][4] When behavioural treatment is insufficient, SSRIs at the usually higher OCD doses may be used, with augmentation by aripiprazole or risperidone in treatment-resistant cases, plus safety monitoring for metabolic and extrapyramidal effects.^[2]

Anxiety and mood disorders are more common in adolescents and adults and in those with greater tic severity; oppositional defiant disorder, autism spectrum characteristics, rage attacks, sleep disturbance and self-injury are all more frequent than in the general population. Screening must be repeated because severity and needs change.^[2][4][6]

All patients and families need education: tics are a neurological, not psychological, phenomenon; they wax and wane; peak severity is usually around ages 10–12; and complete disappearance of tics is unusual but severe adult tics are not inevitable. ^[4][6] Management is collaborative. AAN mandates periodic reassessment of need (including discontinuation) and stresses that the least burdensome effective intervention comes first. The 2019 AAN guideline sets out 46 recommendations; the ESSTS 2021 series (Parts I–IV and a summary statement) gives the European counterpart.^[3][4]

AAN recommends informing all patients and caregivers about the natural history of tic disorders (Level A), evaluating impairment from the patient's and caregiver's perspective (Level A), and offering watchful waiting as acceptable when tics cause no functional impairment (Level B). CBIT may be offered even when impairment is low, if the patient is motivated (Level C). Teachers, peers and students should receive psychoeducation, which improves knowledge and attitudes; resources from patient organisations are recommended. ^[4] ESSTS reports similar emphases and notes that only 57% of specialist centres had behavioural therapy available, despite 89% of experts combining or moving to medication for severely affected patients.^[1][3]

CBIT combines habit reversal training, relaxation and a functional intervention for situations that sustain or worsen tics. It trains awareness of the premonitory urge followed by a competing behaviour. AAN and ESSTS both recommend CBIT as the initial behavioural intervention where available: 8 sessions over about 10 weeks in the child and adult trials, with longer courses for severe tics, poor tic awareness, low motivation or substantial comorbidity; gains are usually maintained at 6 months.^[4][5] The treatment effect is comparable to medicines (meta-analyses find standardised mean differences of roughly 0.67), and the adverse-effect burden is negligible, but motivation, access and cost are barriers.^[5] Exposure and response prevention, which gradually increases urge tolerance, is an acceptable alternative if CBIT is unavailable, and telehealth delivery may improve access.^[4]

CBIT is recommended as an initial treatment option relative to medicines for clinically impairing tics, and as an initial option even when psychosocial or physical impairment is low if the patient is motivated. Providing treatment as early as possible is not supported by evidence of greater efficacy; tics may remit in adolescence without early intervention.^[4]

Clonidine and guanfacine are noradrenergic alpha-2 agonists with reasonable evidence for tic reduction, and their benefit is larger when ADHD coexists (pooled alpha-2 agonist effect size roughly 0.68 in combined tics-plus-ADHD groups versus 0.15 when ADHD is excluded, from the meta-analysis quoted in the AAN review). AAN states that physicians should counsel patients that these medicines may help both conditions (Level B), should prescribe them when benefits outweigh risks, must monitor heart rate and blood pressure (Level A), and must taper gradually to avoid rebound hypertension (Level A).^[4] Guanfacine extended release also requires QTc monitoring in people with cardiac disease, QT-prolonging medication or family history of long-QT syndrome.^[4] Clonidine is more sedating than guanfacine, while guanfacine extended release can prolong the QT interval.^[5]

Typical adult dosing of clonidine/guanfacine for tics is not provided in the AAN summary. ESSTS 2021 Part III describes titration and monitoring, but consistent exact dose tables are not given by the guidelines; local formularies and weight-based instructions must be followed. Alpha-2 agonists are usually used in relatively mild tics, selected to avoid excessive sedation, and withdrawn gradually because rebound hypertension is a risk.^[4][5] Common adverse effects are sedation, dizziness, hypotension, bradycardia and dry mouth.^[4][5]

Dopamine receptor antagonists or partial agonists remain effective second-line treatments. The AAN review assigns "probably" benefit to haloperidol, risperidone, aripiprazole and tiapride, and "possibly" benefit to pimozide, ziprasidone and metoclopramide; neither the AAN nor ESSTS 2021 finds clear superiority of one agent over another. Adverse effects differ by agent and dose: extrapyramidal movement disorders (often with haloperidol, pimozide, risperidone), weight gain and metabolic disturbance (risperidone and aripiprazole), somnolence (risperidone, aripiprazole, tiapride), QT prolongation (pimozide) and raised prolactin (haloperidol, pimozide, metoclopramide).^[4][2] ESSTS 2021 Part III emphasises a shift over the last decade toward aripiprazole, which has lower extrapyramidal risk than first-generation antipsychotics, and lists aripiprazole as the most common first choice in its expert survey, followed by risperidone, clonidine, guanfacine in children and topiramate in adults. Haloperidol remains the only formally licensed drug for tics in most European countries but is no longer a preferred first-line agent there (used by 10% of specialists for children and 12% for adults).^{[1][2][3] [5]}

AAN guidance for antipsychotics: they may be prescribed for tics when benefits outweigh risks (Level C); patients must be counselled on the relative propensity for extrapyramidal, hormonal and metabolic adverse effects (Level A); the lowest effective dose must be used (Level A); monitoring should follow evidence-based protocols for movement disorders and metabolism (Level B); ECG and QTc before and after starting pimozide or ziprasidone and with QT-prolonging co-medication (Level A); and tapering over weeks to months is required on discontinuation to avoid withdrawal dyskinesias (Level B).^[4]

Quantified trial data include a 5–10 mg daily (low-dose) and 10–20 mg daily (high-dose) aripiprazole arms in a phase 3 trial in adolescents, risperidone producing roughly a 36% mean reduction in YGTSS total tic score in a trial of children and adults, and topiramate typically used at 25–150 mg daily. ^[5] Close follow-up should screen for movement disorder, weight and metabolic status, sleep and hormonal effects. Reinforce that antipsychotics do not cure tics, that their effect can be partial, and that "least exposure for the shortest time" is the aim.^[2][4][5]

Topiramate (25–150 mg/day) is a reasonable option for mild tics or when other medicines are not tolerated; cognitive and language problems, somnolence, weight loss and kidney stones are the main risks. Botulinum toxin is useful for single, very troublesome motor or phonic tics in adolescents and adults: it reduces tic frequency and premonitory urges and lasts 12–16 weeks, after which injection must be repeated; local weakness and hypophonia are expected. Cannabinoid products have limited evidence restricted mainly to adults, with disappointing recent trial results and legal variation; VMAT2 inhibitors (tetrabenazine, deutetrabenazine, valbenazine) are used off-label in some centres, carry no tardive dyskinesia risk but no approved indication. Deep brain stimulation targeting the anteromedial or ventroposterolateral globus pallidus, or the centromedian thalamus, is reserved for a very small minority (under 3% of referred patients) with severe, treatment-refractory, disabling tics, after multidisciplinary assessment; no consensus target exists and benefit must be weighed against infection and hardware risk.^[3][4][5]

• Monitor for drug interactions: antipsychotics, dopamine antagonists and QT-prolonging agents combine to raise arrhythmia risk.
• Screening for anxiety, mood and behaviour disorders, suicidality and impulse control must be done at baseline and repeated, and suicidal thoughts actively managed.^[4]
• Co-existing ADHD or OCD treatment should run in parallel, not sequentially; many motor and phonic tics improve once attention, anxiety and family accommodation are addressed.^[2][4]
• DBS should be considered only after multiple classes of medicine and behavioural therapy have failed or are contraindicated, with psychiatric monitoring before and after surgery.^[4]

• Social and academic. Teasing, bullying, exclusion, under-achievement and reduced quality of life; education plans, accommodations and peer psychoeducation reduce harm. ^[4]
• Physical. Pain, fatigue, musculoskeletal strain, joint and muscle injury from thousands of motor tics per day; rare but serious self-injury. ^[5][6]
• Psychiatric. ADHD, OCD, anxiety, depression, oppositional defiant disorder, autism traits, rage, self-injury, and an increased risk of suicidal ideation and attempt. ^[2][4][6]
• Iatrogenic. Sedation, rebound hypertension, QT prolongation and extrapyramidal effects from alpha-agonists and antipsychotics; prolonged antipsychotic use increases movement disorder, weight and metabolic risk, although long-term metabolic studies in Tourette syndrome specifically are reassuring only in part. ^[4][5]
• Functional-tic confusion. Late diagnosis means years of inappropriate treatment, unnecessary tests and blame before the correct framework is applied. ^[6]

The course is variable but overall favourable. Tics usually begin at ages 3–8, with peak severity around age 10 (mean 10, standard deviation 2.4) or between 10 and 12 years; complex tics and phonic tics appear 1–2 years after simple motor tics. ^[4][6] Up to 80% of children who present with a tic disorder before age 10 have a significant decrease in tics during adolescence, and by age 18 most people have only mild residual tics or remission: one longitudinal study found 17% complete remission after age 16, 60% still mild or moderate tics, and up to 23% severe persistent tics into adulthood. ^[1][6] Severity of tics and most comorbidities often improve with age, but a subgroup has lifelong disability. ^{[6] [5]}

Poorer outcome is associated with early onset, greater childhood severity, family history of Tourette syndrome, co-existing ADHD or OCD, teasing and psychosocial stress, female sex in some cohorts, and absence of remission by late adolescence. ^[2][6] The majority of adults live independently; a small minority need lifelong neurological or psychiatric input.

There is no vaccine or primary prevention for Tourette syndrome. What can be done is secondary prevention of harm: early accurate diagnosis, rapid treatment of comorbid ADHD and OCD, school and workplace accommodations, and active prevention of bullying, self-injury and suicide. Screening everyone is not supported; targeted screening is recommended for children and adolescents with known tics, first-degree relatives of affected individuals, and children with suggestive patterns (simple motor tics, excessive blinking) combined with neurodevelopmental or psychiatric symptoms. ^[2][4][6]

Tics often begin between 3 and 8 years and peak at 10–12. In very young children, suppression training can be difficult, so parent-based strategies and education come first. CBIT can be used in younger children but has little trial evidence under age 9. ^[4] Routine speech and language, educational psychology and, where needed, occupational therapy should be added; motor tics reduce handwriting quality and mathematics performance. ^[2]

Adolescence is when comorbid mood and anxiety disorders often emerge and when tic peak and then decline. This is the time to recheck diagnosis, reassess medicines (which may become unnecessary), and support education and autonomy. ^[4][6]

Tourette syndrome is often milder in older adults, but a small group has persistent severe tics and requires the same stepped care, with a lower threshold for careful, small-dose pharmacological therapy and for alpha-agonist-avoidant choices in the presence of cardiovascular disease. ^[4][6] Botulinum toxin may be especially useful for single focal tics in this group.

The current guidelines reviewed here do not provide pregnancy-specific recommendations. Where a woman has a tic disorder and becomes pregnant, decision-making should be shared between psychiatry/neurology and obstetrics, and medicines should generally be minimised or stopped where tics are tolerable, with resumption after delivery if needed. Non-pharmacological approaches remain the preferred approach throughout. Family history taking should cover the risk of inheriting the disorder.

• Reliable psychoeducation and community support cost little and may be the only treatment available. Use family organisations, teachers and translated materials where possible.
• CBIT can be delivered in group or by telehealth; brief habit-reversal elements (awareness plus a competing response) can be taught by a nurse or psychologist even without a formal service. ^[4]
• Diagnosis remains clinical; do not waste money on brain scans for uncomplicated tics. ^[2]
• When medicines are unavailable, use non-medical measures and, if pharmacological therapy is available locally, alpha-agonists before antipsychotics where feasible. ^[4][5]
• Watch for self-injury, bullying and suicide even when full services are lacking; these red flags justify referral. ^[4]

• Tourette syndrome is a neurodevelopmental tic disorder: motor plus phonic tics for more than 12 months before age 18, excluding secondary causes.
• It is common in childhood (about 0.3–1%), male-predominant (ratio 3:1 to 4.3:1), and onsets around ages 3–8 with peak around 10–12.
• "Pure" Tourette syndrome is uncommon: up to 88% have at least one additional psychiatric disorder, and 58% have two or more; ADHD and OCD dominate.
• Tics wax and wane, often suppressible, usually preceded by a premonitory urge; many remit by adulthood (only 17% remit completely after age 16).
• Diagnosis is clinical; routine imaging, EEG and blood tests are unnecessary unless red flags exist; YGTSS is the standard severity measure (total tic score 0–50; global impairment 0–50).
• CBIT is the treatment with the strongest evidence and recommended before medication; the effect size is roughly 0.67 and gains often last 6 months.
• Alpha-2 agonists (clonidine, guanfacine) help both tics and ADHD; monitor heart rate and blood pressure and taper to stop.
• Antipsychotics are second line; use the lowest effective dose, with monitoring for movement disorder, weight, metabolism and QT as indicated; taper over weeks to months. ^[5]
• Haloperidol is the only formally licensed drug for tics in many European countries, yet aripiprazole has overtaken it as the preferred first-line medicine in expert practice.
• Topiramate, botulinum toxin for focal tics, and DBS in refractory cases complete the stepped-care spectrum.
• Complications are mostly social and psychiatric, not medical, and are the main source of disability.
• Screening for ADHD, OCD, anxiety, depression, self-harm and suicidality is mandatory and repeated.

• Attention-deficit/hyperactivity disorder (ADHD)
• Obsessive-compulsive disorder (OCD)
• Autism spectrum disorder
• Functional movement disorders
• Pediatric acute-onset neuropsychiatric syndromes (PANS/PANDAS)
• Childhood epilepsy and movement disorders
• Quality of life in neurodevelopmental disorders